Background: Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab. Materials & methods: A total of 30 patients were enrolled in the study: 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months. Results: The omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers. Conclusion: Omalizumab allowed an improvement of urticaria and mental comorbidities.

Diluvio, L., Piccolo, A., Marasco, F., Vollono, L., Lanna, C., Chiaramonte, B., et al. (2020). Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria. FUTURE SCIENCE OA, 6(9), FSO618 [10.2144/fsoa-2020-0087].

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

Niolu C.;Campione E.;Bianchi L.
2020

Abstract

Background: Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab. Materials & methods: A total of 30 patients were enrolled in the study: 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months. Results: The omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers. Conclusion: Omalizumab allowed an improvement of urticaria and mental comorbidities.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35
English
CSU
DLQI
H1-anti-histamine
HADS
Hospital Anxiety and Depression Scale
UAS7
anxiety
chronic spontaneous urticaria
depression
omalizumab
psychiatric disorders
Diluvio, L., Piccolo, A., Marasco, F., Vollono, L., Lanna, C., Chiaramonte, B., et al. (2020). Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria. FUTURE SCIENCE OA, 6(9), FSO618 [10.2144/fsoa-2020-0087].
Diluvio, L; Piccolo, A; Marasco, F; Vollono, L; Lanna, C; Chiaramonte, B; Niolu, C; Campione, E; Bianchi, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Improving of psychological status and inflammatory biomarkers during omalizumab.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 297.36 kB
Formato Adobe PDF
297.36 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/304474
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact